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This review summarizes the technologies in use and in the pipeline for the management of diabetes. The review
focuses on glucose meters, continuous glucose monitoring devices, insulin pumps, and getting clinicians
connected to technologies. All information presented can be found in the public domain, and was obtained from
journal articles, websites, product review tables in patient publications, and professional conferences. The
technology concerns, ongoing development and future trends in this area are also discussed.
Keywords: Diabetes technology, Continuous glucose monitoring, Insulin pump, Blood glucose meter, New
therapies, Inhaled insulin, Insulin patch, Insulin pill, SmartInsulinThis review summarizes currently available glucose
monitoring and insulin delivery devices and discusses
their advantages and disadvantages. It also highlights the
“next generation” products under different stages of de-
velopment. All information was obtained from the pub-
lic domain.
I. Blood glucose monitoring devices
Optimal diabetes management relies on accurate glucose
monitoring devices. Advances in blood glucose (BG)
monitoring technology have resulted in improved accur-
acy, smaller required blood volumes, and the ability to
transfer data between the BG meter and insulin delivery
devices.
A. Capillary blood glucose monitoring
Devices
Current home BG meters use capillary blood samples
ranging from 0.3-1.5 microliters [1]. The sample is ana-
lyzed using either a glucose oxidase or a glucose de-
hydrogenase reaction. Some strips use the enzymatic/
biosensor reaction alone, while others convert the en-
zymatic reaction into an electrochemical signal first [2].
Although whole blood is used, the meter output is cali-
brated to provide results that correlate with plasma* Correspondence: rubhep@gmail.com
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distribution, and reproduction in any mediumglucose values. Subtle differences exist among meter
performances, such as the ability to withstand
temperature extremes and accuracy at higher altitudes.
Additionally, certain substances interfere with test strip
accuracy. An altered hematocrit will falsely alter the BG
in the same direction. Maltose, ascorbate, and acetomi-
naphen interfere with the enzymatic reaction on the test
strip, greatly affecting the accuracy of the BG reading
[3,4]. A combination of interfering substances can have
up to a 193% impact on the accuracy of the BG reading
[3]. Despite slight variations in meter advantages, all of
the currently FDA approved meters are within 10-15%
of actual laboratory plasma glucose values. A reference
table of currently available BG meters is published by
Diabetes Health every January [1].Enhanced devices Meter capability is continuously
being enhanced. The Freestyle InsuLinx, approved in
Europe in 2011, allows patients to program their insulin-
to-carbohydrate ratio, correction factor, and target BG
into the meter. This information enables the meter to
recommend the next insulin dose based on BG and
carbohydrate intake [5]. A simplified version of the Free-
style InsuLinx, FDA approved in March 2012 and avail-
able for use in the US, works as a meter with a touch
screen electronic logbook without bolus calculation cap-
abilities. The One Touch Verio IQ meter, approved in
the US and Canada in February 2012, recognizesioMed Central Ltd. This is an Open Access article distributed under the terms of
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to them [6].Cell phone-enhanced meters The LG KP8400 cell
phone add-on has been available in Korea since 2002,
and the Infopia LG Glucophone/JVAGO 5965 has been
advertised for the US market since 2008. The meter
piece is attached to the back of the phone, near the bat-
tery pack. Readings are displayed on the cell phone and
can be uploaded to an online database [7]. This device is
currently unavailable in the US. The European,
Bluetooth-enabled GlucoTel system enables wireless
transmission of glucose values from a BG meter to a
web-based logbook using the individual’s mobile phone
as the communication hub [8]. The iBG Star meter and
app, recently developed by Sanofi-Aventis, allows certain
smartphones (iPhone or iTouch) to serve as the BG
meter [9].Plug-and-play devices The iBG Star meter is one type
of plug-and-play device, as the meter must be plugged
into a smartphone in order to function. The smartphone
serves as this meter’s screen. Another type of plug-and-
play device is the Ascensia Contour USB meter, which is
a blood glucose meter that also has a USB drive and
contains software within it so BG data can be down-
loaded to a computer without the need of additional
software/cables.Combination devices In the past, Novo Nordisk part-
nered with Lifescan and created a device called the
InDuo, which was the world’s first combined BG meter
and insulin delivery device. The meter debuted in 2002,
and for undisclosed reasons was discontinued in 2006
[10]. BG meters that double as remote controls for insu-
lin pumps are currently available (see below). After a
several year hiatus, BG meter/insulin delivery combin-
ation devices are now being revisited [11].Communication with other devices Radiofrequency
technology is used to transfer BG data to insulin pumps;
all currently available insulin pumps are enabled with
this feature. The Medtronic MiniMed pumps’ associated
meters (One Touch UltraLink and Ascensia Contour
next link) send BG values to the pump to be incorpo-
rated into the calculation of the insulin dose. The Ani-
mas One Touch Ping, OmniPod PDM, and Accu-Chek
Aviva Combo meters serve as the remote control to the
pump itself. The Animas Vibe and Medtronic MiniMed
Paradigm systems receive information from their paired
real-time continuous glucose monitoring transmitters
and display the information on the pump’s screen.Future directions/under development
The newest BG monitoring devices on the market and
some of those under development appear in Table 1
[5,6,9,12-23].
Non-invasive glucose monitoring is the goal of the fu-
ture. Past attempts at non-invasive glucose monitoring
failed to reliably separate glucose values from noise
without an actual blood sample. Scientific and techno-
logical progress have allowed for other, different techni-
ques to be tried, which overcome difficulties faced in the
past [24]. Some of the devices under development are
truly non-invasive, while others require something to be
injected or implanted under the skin to enable glucose
detection (Table 1, [15-23]).
Connecting meters to clinicians and caregivers
GlucoMON, a system developed by Diabetech in 2006,
connects One Touch Ultra BG meters to clinicians and
caregivers in real time, using 3G cell phone networks to
transmit the data to cell phones, e-mails, and pagers
[25,26]. The GlucoTel system wirelessly sends BG’s to a
web-based logbook using the patient’s mobile phone as
the server [8]. The newly available Telcare system uses
3G cell phone networks to enable two-way communica-
tion between the meter and smartphones and its web-
based server. Clinicians can access their patients’ infor-
mation through the website and can customize messages
that appear on their patients’ meters every time a BG is
checked [13,14]. Other online diabetes management
software exists, including Cerner [27], Diasend [28], and
Carelink [29]. These systems all require the user to ac-
tively upload their devices (instead of data being sent
automatically). The reports can be seen by patients and
clinicians alike provided the clinician has access to the
patient’s report. There are some limitations as to which
devices can be uploaded into these programs. Carelink
can only be used for the Medtronic MiniMed insulin
pumps, glucose sensors, and related BG meters [29];
Cerner and Diasend allow for upload of the Animas in-
sulin pump and most commonly used BG meters
[27,28].
In the office, clinicians can download data from BG
meters using proprietary software and cables. The pro-
grams can be installed on individual computers or net-
worked to several computers, and comprehensive
reports can be both printed and saved. If patients use
these programs at home, reports can be e-mailed to their
clinicians for review.
B. Continuous glucose monitoring (CGM)
Basic CGM
Real-time continuous glucose monitoring (RT-CGM)
allows for continuous measurement of interstitial glu-
cose concentrations. A small, enzyme-coated filament
Table 1 Innovative new blood glucose monitors (existing & under development)
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Table 1 Innovative new blood glucose monitors (existing & under development) (Continued)
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interstitial glucose through a glucose oxidase reaction.
The electrochemical signal is transmitted to a receiver
using radiofrequency, where it is converted into a glu-
cose value. The receiver can be an insulin pump (Med-
tronic Paradigm system, Animas Vibe system) or it can
be a stand-alone unit (DexCom, Freestyle Navigator,
Medtronic Guardian). The Medtronic’s iPro is a blinded
system used by clinicians for diagnostic or research pur-
poses. Sensor glucose values are updated every 1–5 min-
utes. Sensor electrodes can remain in the body for 3–7
days [30].
RT-CGM systems must be calibrated at regular inter-
vals with a fingerstick BG value, both for accuracy and
in order to continue giving the user information. Sensor
glucose values are generally within 20% of actual BG
values [30-36].
Benefits
RT-CGM is clinically useful in identifying post-prandial
hyperglycemia, overnight hypoglycemia, hypoglycemia in
those with hypoglycemia unawareness, and daily glucose
trends. Studies show that patients with type 1 diabetes
who use RT-CGM at least 60-70% of the time have sig-
nificant improvements in glycemic control [37-44]. A re-
cent study found sensor use even 41-60% of the time to
have beneficial glycemic effects [45]. Early studies found
that patients who are at least 25 years of age experienced
the greatest benefits from RT-CGM use [37-41]. This
was hypothesized to be due to increased RT-CGM use
and better adherence to treatment in adults compared
with children and adolescents [40]. Newer studies have
shown glycemic benefits of RT-CGM in all age groups
[46]. In a sample of pediatric patients, Ramchandani
et al. [47] found that although only 21% of all subjects
who had a sensor used it continuously, 76% of subjects
who owned a sensor believed that using RT-CGM
helped them to better manage their diabetes.
Disadvantages
The difficulty with RT-CGM is getting patients, espe-
cially children and adolescents, to use it on a regularbasis for extended periods of time. In many, the fre-
quency of RT-CGM use decreases over time, especially
when patients experience frustration with the system.
The major reasons cited for disuse of RT-CGM are that
patients found it annoying, a hassle, and interfering with
their lives. Those who stop using it do so because of
problematic equipment, insurance issues, and inaccuracy
[47]. These issues need to be addressed before RT-CGM
is embraced more universally.
Connecting CGM to clinicians
Current CGM devices can be uploaded into device-
specific software programs and shared with clinicians ei-
ther as PDF or Word documents (attached to an e-mail
or sent by fax), as web-based reports (Medtronic Mini-
Med CGM devices only), or during an office visit. Glu-
cose sensors can only be downloaded by proprietary
programs, and CGM data fails to integrate with elec-
tronic medical record databases.
Future directions/under development
The goal of RT-CGM is to develop smaller, more accur-
ate devices. Technologies under consideration include
an enhanced transdermal system (Symphony tCGM,
[48,49]), multiple optical sensors using impedance spec-
troscopy (Table 1, [50]), an optical fluorescence fiber-
optic biosensor using fluorophore-labeled glucose/gal-
actose binding protein technology [51] which is shown
to be >95% accurate in vitro [52], non-enzymatic glucose
sensors based on nickel (II) oxide electrospun nanofibers
[53] and nickel nanoparticles on carbon nanotubes [54],
and a small (3.6 mm x 8.7 mm) continuous osmotic in-
jectable/implantable glucose sensor whose performance
is reliable in vitro for up to four weeks [55]. Addition-
ally, intravascular glucose sensors for use in the critical
care setting in the hospital are in the works [56]. More
accurate RT-CGM devices are needed and have great
potential for use both with and without an artificial
pancreas.
Connecting CGM to insulin delivery, including closed-
loop Some insulin pump companies have already
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in the first steps towards an artificial pancreas. The
Medtronic MiniMed Veo pump, available in Europe,
Australia, and Canada, suspends basal insulin delivery
for two hours if the sensor glucose is below a set level
and the individual with diabetes fails to respond or the
sensor glucose remains low for a given amount of time.
Two insulin pump/glucose sensor devices are currently
approved for patient use and many more are currently
under development. The Juvenile Diabetes Research
Foundation (JDRF)’s proposed steps towards develop-
ment of the artificial pancreas include: 1) a sensor-
augmented pump that will shut off for a specific amount
of time when the user does not respond to a low glucose
alarm, 2) a hypoglycemia minimizer that adjusts insulin
delivery when a low glucose is predicted, 3) a hypo-
glycemia and hyperglycemia minimizer that will decrease
insulin delivery if a low glucose is predicted and increase
it if a high glucose (e.g., >200 mg/dl) is predicted, 4) a
hybrid closed loop, where the user manually assists the
system by bolusing for food intake, 5) a fully automated
closed loop with insulin only, and 6) a fully automated
multi-hormone closed loop system [57]. Currently, Step
1 is commercially available in Europe, Australia, and
Canada (the Medtronic Veo system), and Steps 2–6 exist
in research studies.
II. Insulin delivery devices
A. Insulin pumps
Insulin pumps are the most physiologic means currently
available for insulin delivery. Advancements in technol-
ogy have transformed what in 1964 was once a large
piece of equipment to a small, beeper-sized device that
delivers both basal and bolus insulin. User input is es-
sential for a pump to function optimally.
Today’s pumps are available in both wired (with exter-
nal tubing, e.g., Animas, Medtronic MiniMed, Roche)
and wireless (without external tubing, e.g., OmniPod)
versions. The wired pumps are attached to the body
using an infusion set. The current wireless (patch)
pumps are about the size of a small computer mouse,
and are attached directly to the body without any tubing
in between. A small catheter is inserted subcutaneously
from the underside of the patch pump by pressing a but-
ton on the remote control. This serves as the patch
pump’s infusion set. Today, basal rates can be titrated in
as small as 0.025-unit increments, and boluses can be
given in 0.05-unit increments. Wired pumps can be
detached from the site for showers, water sports, and
other activities. Currently available patch pumps remain
on the body and are waterproof.
Existing insulin pumps allow the user to enter their
carbohydrate intake and their BG, and the pump calcu-
lates the insulin dose based on their settings. MedtronicMiniMed and Animas both have sensor-augmented
pumps available, wherein interstitial glucose readings are
checked every five minutes and displayed on the pump’s
screen. The Medtronic MiniMed Veo, which is only
available outside of the US, has an auto-shutoff feature if
the sensor glucose is low and the user does not respond.
Benefits
Many studies have found better glycemic control and/or
better quality of life in patients who use insulin pumps
compared to those on multiple daily injections (MDI)
[58-79]. However, other studies have failed to show im-
provement in glycemic control compared to MDI [80-
84]. Even without improvements in glycemic control, the
quality of life benefits offered by insulin pump therapy
are worthwhile [85,86]. Insulin pumps are easy to use in
insulin-requiring patients of all ages, including infants
[74-76].
Sensor-augmented pumps improve glycemic control,
but only when the sensor is worn at least 41-60% of the
time [39,45]. Both adult and pediatric patients with dia-
betes have attained metabolic benefits using these
devices [46].
Disadvantages
The biggest potential downside to insulin pump therapy
is being tethered to a device, and the fact that the pres-
ence of this device is a constant reminder that one has
diabetes. However, few patients discontinue insulin
pump therapy because of these issues [87,88]. Rapid
onset of ketoacidosis (DKA) can occur within 7–8 hrs
with insulin pump therapy if there is an infusion set or
insulin delivery malfunction [89,90] because there is no
long acting insulin to provide a safety net as with MDI
[86,91].
Future directions/under development
Recently, there has been an explosion of new products
being developed in the insulin pump market (Table 2)
[31,92-105]. Companies continuously strive to improve
upon existing wired insulin pumps by adding meters
that double as full-service remote controls for the pump
itself (Roche Accu-Chek Combo), becoming sensor-
enhanced with easy-to-read output on the pump’s screen
(Animas Vibe + the Dexcom G4 sensor), improving on
the pump’s hardware to make it lighter and more failsafe
(Spring ADI pump), making pump therapy easier by
using pre-filled insulin cartridges (Asante’s Pearl pump),
and improving on the size, interface, and usability of the
pump (Tandem’s t:slim pump).
Until recently, infusion sets have remained more or
less unchanged over the past several years. Spring’s
newly FDA-approved 90-degree luer-lock infusion set is
designed to detect site detachment by occluding the
Table 2 Innovative new insulin pumps (existing & under Development)
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[106].
Many companies are working on patch pumps. The
proprietary nature of this information precludes com-
pleteness of this list. However, all publicly available in-
formation is outlined in Table 2. These pumps strive to
improve on existing patch pump technology by being
detachable (Roche/Medingo Solo, possibly Cellnovo,
Debiotech Jewel, others), adding bolus buttons to the
side of the patch pump so insulin can be delivered even
without the remote control (Roche/Medingo Solo,
others), reducing waste by having reusable or recharge-
able parts (Roche/Medingo Solo, Cellnovo, others), hav-
ing a smaller footprint on the body (Debiotech Jewel,
others), changing the dimensions so it can hold larger
amounts of insulin (Debiotech Jewel holds 450 units),
and working with existing cell phone platforms so that
another device does not need to be carried (Debiotech
Jewel, others). Some simplistic patch pumps/insulin de-
livery devices that exist (Valeritas V-Go and Calibra’s Fi-
nesse) are aimed more towards patients with type 2
diabetes.
Debiotech is also working on a nanopump, a tiny volu-
metric pump with a pair of check valves that is inte-
grated into a MEMS chip. “The chip is a stack of three
layers bonded together: a silicon on insulator (SOI) plate
with micromachined pump-structures and two Pyrex
cover plates with through-holes” [104].
B. Inhaled insulin
Inhaled insulin formulations have been under develop-
ment for several years, and existing products are able to
mimic both first- and second-phase insulin responses
[107-111]. Pfizer’s Exubera was available in the US mar-
ket for approximately six months, but it was unsuccess-
ful and was discontinued [112] due to large, difficult to
titrate volumes that needed dispensation by a large de-
vice. Other formulations of inhaled insulin are in the
works [107,113-116], and their absorption and action
profiles are excellent [107-111,113-116]. Limitations of
inhaled insulin include difficulty titrating the exact dose
needed, potential absorption issues through alveolar
and/or buccal membranes, the size of the insulin deliv-
ery device itself, and the potential of repeated insulin
dosing causing hypertrophy or other problems in the
lungs [107,117,118]. Additionally, basal insulin must still
be injected despite the use of inhaled insulin.
C. Insulin pills
Insulin is a protein which is degraded by digestive
enzymes and hence must be taken as an injection. How-
ever, by using different sized particles, coverings, and
inhibitors which allow for insulin to be transported
through the gastrointestinal tract, a few companies havedeveloped an insulin pill that is taken by mouth and
works like an injection of quick-acting insulin. Limita-
tions of this preparation include that the pill must be
taken on an empty stomach for proper absorption. Add-
itionally, if the patient has a second helping of food, the
second dose of the insulin pill is not effective because
the food that is already in the stomach prevents its ab-
sorption [119-123]. Insulin pills are not yet FDA
approved.
D. Insulin patches/Transdermal insulin delivery
Transdermal insulin delivery allows insulin to be
absorbed through the skin and can be given anywhere
on the body, regardless of the body composition of the
person with diabetes. Insulin patches can be potentially
used with both rapid-acting and long-acting insulins
[124-126]. However, no matter which insulin is put into
the patch, all insulin patches have worked like basal in-
sulin until recently [127]. Insulin patches are not yet
commercially available.
E. Smart insulin
Initially a creation of a nanotechnology scientist from
MIT and now being developed by Merck, SmartInsulin
is an insulin that has been chemically modified to release
insulin in response to glucose in the bloodstream. The
chemical component attached to the insulin, a bio-
degradable polymer containing sticky sugar groups,
causes it to remain insoluble in the body until a certain
concentration of glucose is reached. The glucose then
attracts the components that make the insulin insoluble,
pulling them away from the hormone and allowing it to
become active. It is believed that this will allow for bet-
ter postprandial insulin coverage while minimizing the
incidence of hypoglycemia, all with only one injection
per day [128,129]. SmartInsulin is still in preclinical
studies.
Conclusion
We are in the midst of a revolution of technological
advancements in diabetes care. This technology boom
and associated variety of diabetes management tools en-
able clinicians to develop new and innovative means of
treating their patients. Additionally, these advancements
have the potential to decrease the burden of diabetes
management on the patients themselves. Advances in
diabetes technology will continue to improve patient
care and its delivery, and may one day lead to fully auto-
mated treatment systems for people with diabetes
mellitus.
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